Belite Bio, Inc

BLTE

$167.33

Name : Belite Bio, Inc

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $6,738,738,176.00

EPSttm : -2.74

Belite Bio, Inc

$167.33

1.25%

$2.11

BLTE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.66

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.2

EPS Last/This Y

-0.63

EPS This/Next Y

5.2

Price

167.29

Target Price

228.89

Analyst Recom

Performance Q

12.51

Upside

-157.1%

Beta

-1.24

Ticker: BLTE

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	BLTE	151.33	N/A	N/A	0
2026-08-31	BLTE	155.64	N/A	N/A	0
2026-09-01	BLTE	156.7	N/A	N/A	N/A
2026-09-02	BLTE	161.45	N/A	N/A	0
2026-09-03	BLTE	171.27	N/A	N/A	0
2026-09-04	BLTE	193.81	N/A	N/A	0
2026-09-08	BLTE	193.37	N/A	N/A	0
2026-09-09	BLTE	183.58	N/A	N/A	0
2026-09-10	BLTE	174.96	N/A	N/A	0
2026-09-11	BLTE	173.19	N/A	N/A	0
2026-09-14	BLTE	172.58	N/A	N/A	0
2026-09-15	BLTE	169.14	N/A	N/A	0
2026-09-16	BLTE	169.12	N/A	N/A	0
2026-09-17	BLTE	169.88	N/A	N/A	0
2026-09-18	BLTE	171.32	N/A	N/A	0
2026-09-21	BLTE	173.36	N/A	N/A	0
2026-09-22	BLTE	175	N/A	N/A	0
2026-09-23	BLTE	168.93	N/A	N/A	0
2026-09-24	BLTE	170	N/A	N/A	0
2026-09-25	BLTE	167.06	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	BLTE	151.65	-19.6	-	-2.95
2026-08-31	BLTE	155.25	-19.6	-	-2.95
2026-09-01	BLTE	156.97	-19.6	-	-2.95
2026-09-02	BLTE	160.81	-19.6	-	-2.95
2026-09-03	BLTE	170.71	-19.6	-	-2.95
2026-09-04	BLTE	193.65	-19.6	-	-2.95
2026-09-08	BLTE	192.97	-18.3	-	-2.94
2026-09-09	BLTE	183.32	-18.3	-	-2.94
2026-09-10	BLTE	174.96	-18.3	-	-2.94
2026-09-11	BLTE	173.46	-18.3	-	-2.94
2026-09-14	BLTE	172.91	-18.3	-	-2.94
2026-09-15	BLTE	169.45	-18.3	-	-2.94
2026-09-16	BLTE	169.45	-18.3	-	-2.94
2026-09-17	BLTE	170.14	-18.3	-	-2.94
2026-09-18	BLTE	171.12	-18.3	-	-2.94
2026-09-21	BLTE	173.08	-18.3	-	-2.94
2026-09-22	BLTE	175.18	-18.3	-	-2.94
2026-09-23	BLTE	168.93	-18.3	-	-2.94
2026-09-24	BLTE	169.60	-18.3	-	-2.94
2026-09-25	BLTE	167.29	-18.3	-	-2.94
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	BLTE	-6.89	0.96	2.82
2026-08-31	BLTE	-6.89	0.95	2.82
2026-09-01	BLTE	-6.89	0.95	2.82
2026-09-02	BLTE	-6.89	0.95	2.82
2026-09-03	BLTE	-6.89	0.95	2.82
2026-09-04	BLTE	-6.89	0.95	2.82
2026-09-08	BLTE	-6.89	0.96	2.82
2026-09-09	BLTE	-6.89	0.96	2.82
2026-09-10	BLTE	-23.32	0.96	2.82
2026-09-11	BLTE	-23.32	0.96	2.66
2026-09-14	BLTE	-23.32	0.94	2.65
2026-09-15	BLTE	-23.42	0.94	2.65
2026-09-16	BLTE	-23.42	0.94	2.65
2026-09-17	BLTE	-23.42	0.94	2.65
2026-09-18	BLTE	-23.42	0.94	2.65
2026-09-21	BLTE	-23.42	0.93	2.65
2026-09-23	BLTE	-23.42	0.93	2.65
2026-09-24	BLTE	-23.42	0.93	2.65
2026-09-25	BLTE	-23.42	0.93	2.66
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.7

Avg. EPS Est. Current Quarter

-0.77

Avg. EPS Est. Next Quarter

-0.9

Insider Transactions

-23.42

Institutional Transactions

0.93

Beta

-1.24

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.4

Max Drawdown 5-Year %

Target Price

228.89

P/E

Forward P/E

88.07

PEG

P/S

P/B

8.68

P/Free Cash Flow

EPS

-2.73

Average EPS Est. Cur. Y

-2.94

EPS Next Y. (Est.)

2.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.59

Return on Equity vs Sector %

-39.3

Return on Equity vs Industry %

-19.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.36

EBIT Estimation

◆ BLTE Healthcare

$167.33

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

2/20

Pullback

19/25

Volume

11/15

Valuation

10/20

TP/AR

2/10

Options

0/10

RSI

48.3

Range 1M

39.7%

Sup Dist

0.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

11/30

Estimates

0/20

Inst/Vol

6/15

Options

0/10

EPS Yr

-37.7%

EPS NY

159.8%

52W%

76.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -27.1% upside

Quality

2/30

Valuation

0/30

Growth

7/25

Stability

6/10

LT Trend

1/5

Upside

-27.1%

Quality

BLTE — P/E HistoricalBiotechnology

Belite Bio, Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 41

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE

Latest News

—

Caricamento notizie per BLTE…

stock quote shares BLTE – Belite Bio Inc ADR Stock Price stock today

news today BLTE – Belite Bio Inc ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch BLTE – Belite Bio Inc ADR yahoo finance google finance

stock history BLTE – Belite Bio Inc ADR invest stock market

stock prices BLTE premarket after hours

ticker BLTE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: BLTE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y